| Literature DB >> 28671635 |
Guangwei Zhang1,2, Chenrui Li3, Yinbo Niu4, Qi Yu5, Yulong Chen6, Enqi Liu7,8.
Abstract
A number of medicinal herbs have demonst<Entities:
Keywords: Radix Scutellariae; baicalin; bone marrow derived mesenchymal stem cells; disuse-induced osteoporosis; osteogenic differentiation
Mesh:
Substances:
Year: 2017 PMID: 28671635 PMCID: PMC6152069 DOI: 10.3390/molecules22071044
Source DB: PubMed Journal: Molecules ISSN: 1420-3049 Impact factor: 4.411
Figure 1Measurements of rat body weights within various treatment groups. CON: control group; HLS: hindlimb suspended group; HLS-ALE: group administrated with alendronate (2 mg/kg/day); HLS-RSE: group administrated with Radix Scutellariae extract (50 mg/kg/day). Values are presented by means ± SD, n = 6, * versus CON group: ** p < 0.01.
Figure 2Bone mineral density of proximal tibia (t-BMD) and distal femur (f-BMD) within various treatment groups (g/cm2). CON: control group; HLS: hindlimb suspended group; HLS-ALE: group administrated with alendronate (2 mg/kg/day); HLS-RSE: group administrated with Radix Scutellariae extract (50 mg/kg/day). Values are presented by means ± SD, n = 6, * versus CON group: ** p < 0.01; # versus HLS group: # p < 0.05; ## p < 0.01; ### p < 0.001.
Figure 3Representative 3-D images of bone trabeculain the distal femoral metaphysic region: (A) CON; (B) HLS; (C) HLS-ALE; (D) HLS-RSE (n = 6). CON: control group; HLS: hindlimb suspended group; HLS-ALE: group administrated with alendronate (2 mg/kg/day); HLS-RSE: group administrated with Radix Scutellariae extract (50 mg/kg/day).
Figure 4Measurements of femoral trabecula within various treatment groups: (A) bone volume density (BV/TV); (B) trabecular thickness (Tb.Th); (C) trabecular number (Tb.N); (D) trabecular separation (Tb.Sp), (E) connectivity density (Conn. D) as well as (F) cortical thickness (Cr. Th) (n = 6). CON: control group; HLS: hindlimb suspended group; HLS-ALE: group administrated with alendronate (2 mg/kg/day); HLS-RSE: group administrated with Radix Scutellariae extract (50 mg/kg/day); * versus CON group: * p < 0.05, ** p < 0.01, ***p < 0.001; # versus HLS group: ## p < 0.01, ### p < 0.001.
Effect of RSE treatment on bone biomechanical parameters in rat femoral diaphysis for male and female rats.
| Parameters | CON | HLS | HLS-ALE | HLS-RSE |
|---|---|---|---|---|
| Maximum stress (MPa) | 111.24 ± 13.05 | 89.55 ± 5.28 * | 109.84 ± 16.46 # | 116.37 ± 8.85 ## |
| Young’s modulus (MPa) | 3576.52 ± 237.04 | 2724.98 ± 128.70 * | 3415.29 ± 556.66 # | 3671.41 ± 314.43 # |
| Maximum load (N) | 77.02 ± 9.04 | 61.77 ± 3.70 ** | 80.05 ± 9.38 ### | 80.57 ± 6.13 ### |
| Stiffness (N/mm) | 198.96 ± 18.64 | 120.72 ± 11.50 *** | 210.01 ± 26.34 ### | 196.26 ± 13.39 ### |
CON: control group; HLS: hindlimb suspended group; HLS-ALE: group administrated with alendronate (2 mg/kg/day); HLS-RSE: group administrated with Radix Scutellariae extract (50 mg/kg/day). Values are presented by means ± SD, n = 6; * versus CON group: * p < 0.05, ** p < 0.01, *** p < 0.001; # versus HLS group: # p < 0.05, ## p < 0.01, ### p < 0.001.
Bone turnover markers in rat serum within various treatment groups (n = 6).
| Parameters | CON | HLS | HLS-ALE | HLS-RSE |
|---|---|---|---|---|
| Ca (mM) | 2.46 ± 0.10 | 2.41 ± 0.16 | 2.34 ± 0.123 | 2.37 ± 0.06 |
| P (mM) | 1.82 ± 0.08 | 2.08 ± 0.05 | 1.80 ± 0.21 | 2.04 ± 0.11 |
| BAP (μg/L) | 55.86 ± 1.55 | 55.03 ± 2.56 | 57.41 ± 1.25 | 56.29 ± 5.53 |
| TRACP (pg/L) | 2055.53 ± 172.20 | 2560.55 ± 114.58 | 2178.42 ± 287.16 | 2221.74 ± 203.29 |
| *** | # | # |
Ca: Calcium; P: phosphorus; BAP: bone alkaline phosphatase; TRACP: tartrate resistant acid phosphatase. CON: control group; HLS: hindlimb suspended group; HLS-ALE: group administrated with alendronate (2 mg/kg/day); HLS-RSE: group administrated with Radix Scutellariae extract (50 mg/kg/day). Values are presented by means ± SD, n = 6; * versus CON group: *** p < 0.001; # versus HLS group: # p < 0.05.
Figure 5Effect of baicalin on ALP activity at various concentrations (n = 6). * p < 0.05, ** p < 0.01, *** p < 0.001.
Figure 6Effect of baicalin at various concentrations on mineralized nodule formation 12 days after osteogenic induction. (A) CON; (B) baicalin at 1 μM; (C) baicalin at 10 μM; (D) baicalin at 50 μM.
Intensity scanning of mineralized nodule formation 12 days after osteogenic induction (n = 4).
| Group | Area (mm2/Well) | Number (Mineralized Nodule/Well) | Intensity |
|---|---|---|---|
| CON | 30.34 ± 6.53 | 702.78 ± 49.50 | 21955.34 ± 2397.71 |
| 1 μmol·L−1 | 54.55 ± 6.23 ** | 973.64 ± 74.70 ** | 71181.98 ± 5769.01 *** |
| 10 μmol·L−1 | 68.14 ± 4.93 *** | 1218.64 ± 147.13 ** | 90613.62 ± 6423.42 *** |
| 50 μmol·L−1 | 64.03 ± 5.41 ** | 1157.68 ± 85.70 *** | 74511.73 ± 5773.22 *** |
** p < 0.01; *** p < 0.001 vs. CON.